Notification of first patent grant

RNS Number : 0661Y

SkinBioTherapeutics PLC

30 November 2017

 

SkinBioTherapeutics plc

Notification of first patent grant

Manchester, UK - 1 December 2017 - SkinBioTherapeutics plc (AIM: SBTX,  the "Company"), a life science company focused on skin health, announces the granting of the first patent for its SkinBiotix® technology in Australia.

The patent granted covers the use of specific probiotic bacteria and lysates in the treatment of skin in health and disease. This marks the Company's first patent to progress to grant from within its portfolio of patents pending estate. The patent, numbered 2013246701 and entitled 'Probiotic bacteria', runs until 15 March 2033.

The patent is in active prosecution in other locations worldwide including Europe, USA and China.  

Dr Catherine O'Neill, CEO of SkinBioTherapeutics, commented:

"The Australian skincare market is a key global market. The progression and successful grant of the first national patent to emerge from the Company's Skinbiotix® patent family underpins the commercial potential worldwide.

"This is a step forward in preparing for human trials, which are scheduled for 2018."

This announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014.

-Ends-

For more information, please contact:

SkinBioTherapeutics plc Dr. Cath O'Neill, CEO Doug Quinn, CFO	Tel: [phone]
Cairn Financial Advisers LLP Tony Rawlinson / Emma Earl / Richard Nash	Tel: [phone]
Turner Pope Investments Ben Turner / James Pope	Tel: [phone]
Instinctif Partners Melanie Toyne-Sewell / Deborah Bell	Tel: [phone] [e-mail]

Notes to Editors

About SkinBioTherapeutics plc

SkinBioTherapeutics is a life science company focused on skin health. The Company's proprietary platform technology, SkinBiotix®, is based upon discoveries made by CEO Dr. Catherine O'Neill and Professor Andrew McBain.

SkinBioTherapeutics' platform applies research discoveries made on the activities of lysates derived from probiotic bacteria when applied to the skin.  The Company has shown that the SkinBiotix® platform can improve the barrier effect of skin models, protect skin models from infection and repair skin models.  Proof of principle studies have shown that the SkinBiotix® platform has beneficial attributes applicable to each of these areas. 

SkinBioTherapeutics received seed funding from the Tech Transfer office of the University of Manchester for the discovery of SkinBiotix®. The platform was subsequently spun out of the University of Manchester in March 2016 and was funded by OptiBiotix (AIM: OPTI).

The Company joined AIM in April 2017 concurrent with raising £4.5 million from a placing of new ordinary shares.

The Company is based in Manchester, UK. For more information, visit www.skinbiotherapeutics.com.

 

END

 

 

RESFDMFUSFWSEEF